More Americans are keeping jobs they would otherwise leave for fear of losing their insurance, as healthcare costs rise and non-employer coverage seems less affordable, according to a new poll.
1 in 4 workers stay in unwanted jobs for health coverage, survey finds Read More »
Desde hace décadas, el consenso científico sobre la intensidad con la que la Tierra reacciona a las tormentas solares ha sido que dicha intensidad tiene un límite superior. Sin embargo, un nuevo y alarmante estudio sugiere que este límite superior es una ilusión. S …
Las sustancias perfluoroalquiladas y polifluoroalquiladas (PFAS, por sus siglas en inglés), macabramente apodadas “sustancias eternas” por lo mucho que perduran en el medioambiente después de desecharse los productos de los que forman parte, son un amplio grupo de sustancia …
Un modo de combatir la amenaza de las PFAS, sustancias contaminantes casi eternas Read More »
El sistema solar de Beta Pictoris, ubicado a 63 años-luz de la Tierra, es muy joven. Su edad es de solo 23 millones de años, menos tiempo que el transcurrido desde la extinción de los dinosaurios (66 millones de años). Su extrema juventud ofrece una ventana inusu …
Descubren un tercer planeta alrededor de Beta Pictoris Read More »
En una investigación reciente, se ha descubierto cómo una mutación que inicia el cáncer deja a la célula preparada para formar un tumor, manteniéndola en un estado de espera como una auténtica bomba de relojería biológica. El es …
AdventHealth is expected to have a majority interest in the partnership, which will unite Denver-area hospitals and clinics owned by the two nonprofits. The deal is expected to close early next year.
Intermountain Health, AdventHealth plan joint venture in Denver Read More »
While Johnson & Johnson will go head to head with Intuitive in the U.S., analysts questioned whether its robotic surgery system will take meaningful share from the market leader.
J&J gets FDA authorization for Ottava robot, teeing up competition with Intuitive Read More »
Summit Therapeutics and Akeso are answering questions raised about ivonescimab’s ability to translate to Western populations, though the partners have yet to share if the new findings are statistically significant.
Summit and Akeso sharpen case for ivonescimab with new Western data Read More »
Top-selling cell therapies from BMS, J&J and Gilead depend on a BioLife product, positioning Repligen to use the takeover to increase its exposure to the modality.
Repligen strikes $1.5B BioLife buyout to bag cell therapy product pharmas rely on Read More »
With Phase 3 data showing what analysts called a “potentially best-in-class profile,” Arrowhead Pharmaceuticals plans to submit for FDA approval of plozasiran by the end of the year—hoping to follow to market Ionis Pharmaceuticals’ Tryngolza, which got the regulator’s nod in severe hypertriglyceridemia last month.
Arrowhead puts pressure on Ionis with positive data for triglyceride lowering drug Read More »
